Results 181 to 190 of about 12,515 (211)

Imatinib Mesylate

2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Ahmed H. Bakheit, Badraddin M.H. Al-Hadiya, Ahmed A. Abdelgalil   +2 more
openaire   +3 more sources

Imatinib Mesylate (Gleevec) Hepatotoxicity

Digestive Diseases and Sciences, 2007
Imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corporation, East Hanover, NJ), formerly known as STI571, is a specific inhibitor of BCR-ABL tyrosine kinase. It is widely used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and c-kit (CD117) positive unresectable and/or metastatic malignant ...
Eugene R. Schiff, Ayse L. Mindikoglu, Arie Regev, Enrique J. Martinez, Pablo A. Bejarano, Lennox J. Jeffers   +5 more
openaire   +3 more sources

Role of Imatinib Mesylate in Osteoblastogenesis.

Blood, 2007
Abstract Imatinib mesylate (IM), a tyrosine kinase inhibitor, currently used in chronic myeloid leukaemia (CML) may also affect the growth of other cellular systems besides CML cells. It has been reported that IM may affect bone tissue remodeling mainly by an inhibitory activity on osteoclastogenesis.
D. TIBULLO, C. GIALLONGO, P. LA CAVA, S. BERRETTA, F. STAGNO, A. CHIARENZA, G. A. PALUMBO, DI RAIMONDO, FRANCESCO   +7 more
openaire   +3 more sources

Imatinib mesylate in thymic epithelial malignancies

Cancer Chemotherapy and Pharmacology, 2011
Thymic epithelial tumors (TETs) are rare tumors of the mediastinum, with an estimated incidence of about 3 cases per 100,000 inhabitants. Although anthracycline- and platinum-based chemotherapy is an active treatment for TETs, novel systemic therapeutic options are especially needed for metastatic disease, which is virtually incurable.
PALMIERI, GIOVANNELLA, Marino M., BUONERBA, CARLO, FEDERICO, piera, Conti S., Milella M., Petillo L., Evoli A., Lalle M., Ceribelli A., Merola G., MATANO, ELIDE, Sioletic S., DE PLACIDO, SABINO, DI LORENZO, GIUSEPPE, DAMIANO, VINCENZO   +15 more
openaire   +4 more sources

Imatinib mesylate in the treatment of hematologic malignancies

Expert Opinion on Biological Therapy, 2007
The treatment of hematologic malignancies has been based for many years on chemotherapy and possibly, for the more aggressive forms, stem cell transplantation. In 2001, the signal transduction inhibitor 571 (STI571, imatinib mesylate) was reported to have striking effects in chronic myeloid leukaemia patients.
PICCALUGA, PIER PAOLO, RONDONI, MICHELA, PAOLINI, STEFANIA, ROSTI, GIANANTONIO, MARTINELLI, GIOVANNI, BACCARANI, MICHELE   +5 more
openaire   +4 more sources

Imatinib mesylate-induced acute hepatotoxicity

Journal of Oncology Pharmacy Practice, 2023
Introduction Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated. Case report We report a 51-year-
Imen Frikha, Yousra Fakhfakh, Rim Sahnoun, Lassaad Chtourou, Moez Medhaffar, Moez Elloumi   +5 more
openaire   +2 more sources

Imatinib Mesylate

2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire   +5 more sources

Polycythemia Vera Responds to Imatinib Mesylate

The American Journal of the Medical Sciences, 2003
We report 2 patients with polycythemia vera who were demonstrated to be -negative and were unable to tolerate either hydroxyurea or interferon-alpha but who had excellent clinical responses to imatinib mesylate (STI-571). This effect is consistent with the inhibitory effect of imatinib mesylate on c-kit's tyrosine kinase activity as demonstrated by its
Tina M. Dickinson, C. Michael Jones
openaire   +3 more sources

A validated LC method for imatinib mesylate

Journal of Pharmaceutical and Biomedical Analysis, 2003
An isocratic reversed-phase liquid chromatography method with UV detection has been developed for the purity evaluation of imatinib mesylate in bulk drug. The method is selective and is capable of detecting all process intermediates and other related compounds, which may be present at trace levels in the drug substance.
D Sreenivas Rao, N. M. Sekhar, Ganesan Vaidyanathan, V.V Vivekanand, P Ramachandra Puranik, S Avijit Kelkar   +5 more
openaire   +3 more sources

Keratoacanthomas associated with imatinib mesylate

Acta Oncologica, 2010
To the Editor,Imatinib mesylate, an orally available inhibitor of constitutively activated BCR-ABL tyrosine kinase, platelet-derived growth factor receptor (PDGFR) alpha and beta, and the c-kit rec...
Klaus J. Busam, Yevgeniy Balagula, Jedd D. Wolchok, Richard D. Carvajal, Patricia L. Myskowski   +4 more
openaire   +2 more sources